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Abstract
Objective:  This  study  sought  to  assess  the  effect  of  the  multidimensional  approach
developed  by  the  International  Nosocomial  Infection  Control  Consortium  (INICC)  on
the  reduction  of  ventilator-associated  pneumonia  (VAP)  rates  in  patients  hospitalized
in  an  adult  intensive  care  unit  (AICU)  in  an  INICC  member  hospital  in  Havana,  Cuba.
Methods:  We  conducted  a  prospective  surveillance  pre-post  study  in  AICU  patients.
The  study  was  divided  into  two  periods:baseline  and  intervention.  During  the  base-
line  period,  we  conducted  active  prospective  surveillance  of  VAP  using  the  Centers
for  Disease  Control  and  Prevention  (CDC)  National  Health  Safety  Network  (NHSN)
deﬁnition  and  INICC  methods.  During  the  intervention  period,  we  implementedDeveloping countries;
Adult intensive care
unit;
Multidimensional
approach
the  INICC  multidimensional  approach  for  VAP,  in  addition  to  performing  active
surveillance.  This  multidimensional  approach  included  the  following  measures:  a
bundle  of  infection  control  interventions,  education,  outcome  surveillance,  process
surveillance,  feedback  of  VAP  rates  and  performance  feedback  of  infection  con-
trol  practices.  The  baseline  rates  of  VAP  were  compared  to  the  rates  obtained  after
intervention,  and  we  analyzed  the  impact  of  our  interventions  by  Poisson  regression.
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Results:  During  the  baseline  period,  we  recorded  114  mechanical  ventilator  (MV)  days,
whereas  we  recorded  2350  MV  days  during  the  intervention  period.  The  baseline  rate
of  VAP  was  52.63  per  1000  MV  days  and  15.32  per  1000  MV  days  during  the  intervention.
At  the  end  of  the  study  period,  we  achieved  a  70%  reduction  in  the  rate  of  VAP  (RR,
0.3;  95%  CI,  0.12—0.7;  P  value,  0.003.).
Conclusions:  The  implementation  the  INICC  multidimensional  approach  for  VAP  was
associated  with  a  signiﬁcant  reduction  in  the  VAP  rate  in  the  participating  AICU  of
Cuba.
dulaziz  University  for  Health  Sciences.  Published  by  Elsevier
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bundle of  infection  control  interventions,  educa-
tion,  outcome  surveillance,  process  surveillance
and feedback  regarding  VAP  rates  and  infection  con-©  2013  King  Saud  Bin  Ab
Ltd.  All  rights  reserved.
ntroduction
entilator-associated  pneumonia  (VAP)  is  one  of  the
ost common  device-associated  infections  (DAI)
mong intensive  care  unit  patients,  contributing  to
ubstantial increases  in  hospital  costs  and  length  of
tay (LOS)  [1].  According  to  the  scientiﬁc  literature,
AP is  the  leading  cause  of  morbidity  and  mortality
n the  adult  intensive  care  unit  (ICU)  setting,  both
n developed  [2]  and  developing  countries  [3,4].
According to  a  systematic  review,  the  burden
f VAP  has  not  been  systematically  addressed  in
eveloping  countries  [4].  Although  it  has  been
emonstrated that  surveillance  plays  a  substantial
ole  in  the  reduction  of  VAP  in  the  developed  world
5], in  developing  countries,  its  importance  for
easuring  ICU  patient  infection  risks,  outcomes  and
rocesses  remains  under-recognized  [4,6].  To  coun-
eract the  adverse  effects  of  DAI  in  limited-resource
ountries, in  2002  the  International  Nosocomial
nfection Control  Consortium  (INICC)  developed
 multidimensional  approach  for  DAI  prevention
peciﬁcally devised  for  ICUs  in  developing  countries
7,8].
The results  of  the  INICC  program  showed  that
here was  a  marked  difference  in  the  VAP  rates
etween the  ICUs  of  hospitals  from  the  indus-
rialized world  and  those  from  limited-resource
ealthcare  settings,  whose  rates  were  between  3
nd 5  times  higher  [9—11].
The  INICC  multidimensional  approach  for  VAP
ncludes  an  infection  prevention  bundle  based  on
he preventive  strategies  described  by  the  Society
or Health  Care  Epidemiology  of  America  (SHEA)  and
he Infectious  Diseases  Society  of  America  (IDSA)
12]. Such  recommendations  provide  feasible  and
ost-effective  infection  control  measures  that  are
pplicable  to  limited-resource  ICU  settings.  In  turn,
he INICC  prevention  bundle  follows  the  recommen-
ations of  the  Institute  of  Healthcare  Improvement
IHI) stating  that  a  ventilator  bundle  should  be
mplemented  at  every  ICU  to  reduce  the  incidence
t
V
hf  VAP  to  zero.  These  steps  are  part  of  the  5  Mil-
ion Lives  campaign,  which  has  been  endorsed  by
eading US  agencies  and  professional  societies  [13].
Nevertheless,  very  few  studies  have  shown  suc-
essful  interventions  for  VAP  reduction,  which
ould provide  guidance  to  address  this  problem
4]. Likewise,  study  heterogeneity  in  developing
ountries may  cause  variation  in  the  reported  rates
4].
Within the  context  of  developing  countries,  out-
ome and  process  surveillance  that  is  integrated
nto an  intervention  bundle  containing  performance
eedback of  infection  control  practices  has  been
hown  to  successfully  reduce  and  control  DAIs,  as
hown by  different  studies  conducted  in  INICC  mem-
er hospitals  [14,15].
For  analytical  purposes,  the  World  Bank  classiﬁes
conomies  as  low  income,  middle  income,  or  high
ncome. As  of  1  July  2011,  low-income  economies
re those  that  had  average  incomes  of  $1005
r less  in  2010;  lower-middle-income  economies
ad average  incomes  of  $1006  to  $3975;  upper-
iddle-income economies  had  average  incomes  of
3976 to  $12,275  and  high-income  economies  had
verage incomes  of  $12,276  or  more.  Low-  and
iddle-income  economies  are  commonly  referred
o as  developing  economies.  However,  this  does  not
mply that  economies  in  the  same  income  group
ave reached  similar  stages  of  development  or
hat high-income  economies  have  reached  a  pre-
erred or  ﬁnal  stage  of  development.  This  study
as conducted  in  Cuba,  which  is  classiﬁed  as  an
pper-middle-income  economy.
The current  study  sought  to  advance  the  knowl-
dge of  necessary  scientiﬁc  evidence  in  Cuba
y assessing  the  speciﬁc  impact  of  a  multidi-
ensional approach  for  VAP—–which  includes  arol practices—–on  the  reduction  of  the  incidence  of
AP among  adult  ICU  patients  at an  INICC  member
ospital in  Havana,  Cuba.
t
r
b
t
P
P
a
m
p
s
t
p
c
r
o
l
e
i
w
f
c
h
o
H
t
m
[
r
d
c
a
(
b
c
m
a
p
s
T
I
o
t
c
g
t
B100  
Methods
Setting and  study design
This  pre-post  prospective  cohort  study  was  carried
out in  the  AICU  of  an  INICC  member  hospital  in
Havana,  Cuba.  This  hospital  actively  participated  in
the study  and  employed  an  infection  control  team
(ICT) that  was  comprised  of  a  medical  doctor  with
formal education  in  internal  medicine  and  epidemi-
ology and  2  infection  control  professionals  (ICPs).
The study  period  spanned  from  January  2007
to November  2010  and  was  divided  into  2  phases:
Phase 1  (baseline  period,  consisting  of  the  ﬁrst
three months  of  participation  in  the  INICC  program)
and  Phase  2  (intervention  period).  The  Institutional
Review Board  at  each  hospital  approved  the  study
protocol.
Intervention period
The  intervention  period  began  after  three  months
of participation  in  the  INICC  Surveillance  Pro-
gram. The  length  of  the  intervention  period  was
47 months.  The  INICC  multidimensional  approach
includes the  following  practices:  a  bundle  of  infec-
tion control  interventions,  education,  outcome
surveillance, process  surveillance,  feedback  of  VAP
rates and  performance  feedback  of  infection  con-
trol practices.
INICC methodology
The  INICC  Surveillance  Program  includes  two  com-
ponents:  outcome  surveillance  (VAP  rates  and
consequences)  and  process  surveillance  (adherence
to hand  hygiene  and  other  basic  preventive  infec-
tion control  practices)  [7].
The investigators  at  the  participating  hospital
were required  to  perform  outcome  and  process
surveillance by  completing  forms,  which  were  sent
for monthly  analysis  to  the  INICC  ofﬁce  in  Buenos
Aires  [7].
Outcome surveillance
The  INICC  Surveillance  Program  applies  the  def-
initions  for  DAI  developed  by  the  U.S.  Centers
for Disease  Control  and  Prevention  (CDC)  for  the
National  Nosocomial  Infection  Surveillance  Sys-
tem (NNIS)/National  Health  Safety  Network  (NHSN)
program,  thereby  minimizing  the  potential  surveil-
lance bias  [16,17].  Furthermore,  the  INICC  methods
take into  consideration  the  different  socioeconomic
statuses and  speciﬁc  limitations  of  limited-resource
countries and  were  adapted  for  their  application  in
r
f
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his  setting  [7].  Outcome  surveillance  includes  VAP
ates per  1000  device-days,  microorganism  proﬁle,
acterial  resistance,  length  of  stay  and  mortality  in
he ICU.
rocess surveillance
rocess  surveillance  is  designed  to  monitor  compli-
nce with  easily  measurable,  key  infection  control
easures,  and  it  includes  the  surveillance  of  com-
liance rates  for  hand  hygiene  practices  and  some
peciﬁc infection  control  measures  for  the  preven-
ion of  VAP  [14,15].  In  our  study,  we  collected
rocess surveillance  data  only  on  hand  hygiene
ompliance because  we  did  have  the  necessary
esources to  collect  data  regarding  compliance  with
ther measures  included  in  the  process  surveil-
ance for  VAP  prevention.  Therefore,  we  could  not
valuate the  implications  of  all  the  interventions
ndividually.
Hand hygiene  (HH)  compliance  by  healthcare
orkers (HCWs)  was  determined  by  measuring  the
requency of  HH  performances  when  clearly  indi-
ated, and  such  practices  were  monitored  by  the
ospital’s  ICP  during  randomly  selected  1-hour
bservation periods,  3  times  a week.  Although
CWs know  that  HH  practices  are  regularly  moni-
ored, they  are  not  actually  aware  of  the  precise
oment in  which  the  observations  are  taking  place
7].
ICPs were  trained  to  detect  HH  compliance  and
ecord  HH  opportunities  and  compliance  through
irect observation.  The  INICC  direct  observation
omprises the  ‘‘Five  Moments  for  Hand  Hygiene,’’
s recommended  by  the  World  Health  Organization
WHO). The  ‘‘Five  Moments’’  were  designed  on  the
asis of  the  evidence  concerning  DAI  prevention  and
ontrol and  include  the  monitoring  of  the  following
oments: (1)  before  patient  contact,  (2)  before  an
septic task,  (3)  after  body  ﬂuid  exposure,  (4)  after
atient contact  and  (5)  after  contact  with  patient
urroundings  [18].
raining and validation
nvestigators  were  trained  in  the  INICC  meth-
ds through  a  manual  and  a training  tool
hat described  how  to  perform  surveillance  and
omplete  surveillance  forms.  Furthermore,  investi-
ators had  continuous  e-mail  and  telephone  access
o a  support  team  at  the  INICC  Central  Ofﬁce  in
uenos  Aires,  Argentina,  which  is  responsible  for
eplying to  queries  within  24  h.  The  INICC  Chairman
urther  reviewed  every  question  and  reply.
Surveillance  forms  for  individual  patients  allow
nternal  and  external  validation  because  they
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Sffectiveness  of  a  multidimensional  approach  for  th
nclude  every  clinical  and  microbiological  criterion
or each  type  of  DAI,  such  as  temperature,  blood
ressure, use  of  invasive  devices,  cultures  taken,
ulture  results  and  antibiotic  use.  Surveillance  also
ncludes a  form  where  positive  cultures  are  regis-
ered  and  matched  with  patient  forms.
Every  month,  investigators  from  the  participat-
ng hospital  submitted  the  completed  surveillance
orms to  the  INICC  Central  Ofﬁce,  where  the  valid-
ty of  each  case  was  veriﬁed  and  the  recorded  signs
nd symptoms  of  infection  and  the  results  of  labora-
ory studies,  radiographic  studies  and  cultures  were
crutinized  to  assure  that  the  NNIS  System  criteria
or device-associated  infection  were  met.
Investigators  who  reviewed  the  forms  veriﬁed
hat criteria  for  infection  had  been  met  accurately
n each  case.  Additionally,  the  original  patient  data
orms were  further  validated  at  the  INICC  Cen-
ral Ofﬁce  before  data  on  the  reported  infection
ere entered  into  the  INICC  database.  To  that  end,
ueries were  submitted  from  the  INICC  ofﬁce  in
uenos  Aires  to  the  hospital  investigators,  challeng-
ng cases  with  suspected  VAP.  Data  were  uploaded
nly after  receiving  conﬁrmation  from  hospital
eams. Finally,  the  INICC  team  performed  database
onsistency  analyses  for  factors  such  as  age,  gender
nd dates  and  reviewed  medical  records  that  com-
ared data  registered  in  forms  to  data  in  medical
ecords.
erformance feedback
he  concept  of  using  feedback  from  outcome
urveillance  and  process  surveillance  as  a  valuable
ontrol  measure  in  limited-resource  hospitals  was
ased on  its  effectiveness  in  previous  INICC  studies
14,15].
The INICC  Central  Ofﬁce  team  prepared  and  sent
onthly  chart  reports  to  the  participating  hospital
hat detailed  their  rates  of  VAP,  microbiology  proﬁle
nd rates  of  adherence  to  hand  hygiene.  As  men-
ioned  before,  because  of  our  limited  resources,
e did  not  collect  data  on  the  other  measures  of
rocess  surveillance  for  VAP  prevention.
The participating  ICU  staff  received  feedback  on
heir performance  at  monthly  meetings,  by  means
f the  review  of  patient  charts,  and  the  feedback
as posted  in  a  prominent  location  in  the  ICU.
undle componentsur  bundle  included  the  following  elements:
1. Active  surveillance  for  VAP  [19];
2. Adherence  to  hand-hygiene  guidelines  [20];
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3.  Maintenance  of  patients  in  a  semi-recumbent
position  (30—45◦ elevation  of  the  head  of  the
bed) [12];
4. Performance  of  daily  assessments  of  readiness
to wean  and  the  use  of  weaning  protocols  [21];
5. Performance  of  comprehensive  regular  oral
care with  an  antiseptic  solution  [22];
6. Use  of  noninvasive  ventilation  whenever  pos-
sible  and  the  minimization  of  the  duration  of
ventilation  [12];
7.  Preferable  use  of  orotracheal  instead  to  naso-
tracheal intubation  [23];
8. Maintenance  of  an  endotracheal  cuff  pressure
of at  least  20  cm  H2O  [24];
9. Removal  of  the  condensate  from  ventilator  cir-
cuits [12]  and  keeping  the  ventilator  circuit
closed during  condensate  removal  [25];
0. Change of  the  ventilator  circuit  only  when  vis-
ibly soiled  or  malfunctioning  [26];
1. Avoidance  of  gastric  overdistention  [27];
2. Avoidance  of  histamine  receptor  2  (H2)-
blocking agents  and  proton  pump  inhibitors
[28];
3. Use  of  sterile  water  to  rinse  reusable  respira-
tory equipment  [12];
4. Performance  of  direct  observation  of  hand
hygiene compliance,  duration  of  the  ventila-
tion and  ventilation  ratio  use,  using  structured
observation tools  at  regularly  scheduled  inter-
vals  [7].
As mentioned  above,  because  of  our  insufﬁcient
esources, we  did  not  collect  process  surveillance
ata on  the  components  of  our  bundle  for  VAP  pre-
ention,  with  the  exception  of  hand  hygiene.
eﬁnitions
e  applied  the  CDC  NHSN  deﬁnitions  for  VAP  [17],
hereby  VAP  is  diagnosed  in  a mechanically  venti-
ated patient  with  a chest  radiograph  showing  new
r progressive  inﬁltrates,  consolidation,  cavitation,
r pleural  effusion.  The  patient  also  must  meet
t least  one  of  the  following  criteria:  new  onset
f purulent  sputum  or  change  in  character  of  spu-
um; organism  cultured  from  the  blood;  or  isolation
f an  etiologic  agent  from  a  specimen  obtained
y tracheal  aspirate,  bronchial  brushing  or  bron-
hoalveolar  lavage,  or  biopsy  [17].
tatistical methodsatient  characteristics  during  baseline  and  during
he last  three  months  of  the  intervention  period  in
he ICU  were  compared  using  Fisher’s  exact  test  for
ichotomous  variables  and  an  unmatched  Student’s
102  H.  Guanche-Garcell  et  al.
Table  1  Patient  characteristics,  device  use,  and  ventilator-associated  pneumonia  rates  during  Phase  1  (baseline
period)  and  Phase  2  (intervention  period).
Patient  Characteristics  Baseline  Intervention  RRa 95%  CI  P-Value
Study  period  in  months,  n 3 47  —  —  —
Patients,  n 67 1008 — —  —
aBed  days,  n  363 5648 — — —
bMV  days,  n  114 2350 — — —
cMV  use,  mean  0.31  0.42  1.32  1.1—1.6 0.0032
MV  duration,  mean  ±  SD  1.7  ±  3.0  2.34  ±  4.6  —  —  0.265
Age,  mean  ±  SD  60.0  ±  19.0  61.4  ±  17.6  —  —  0.534
Male  31(46%)  501(50%)  1.07  0.75—1.54  0.7
Female  36(46%)  506(50%)  —  —  —
Pulmonary  disease,  n  (%)  11(16%)  247(25%)  1.54  0.84—2.81  0.16
Abdominal  surgery,  n  (%)  5(7%)  112(12%)  1.54  0.63—3.78  0.34
Chronic  obstructive,  n  (%)  11(16%)  186(19%)  1.16  0.63—2.12  0.64
Trauma,  n  (%)  2(3%)  18(2%)  0.62  0.14—2.68  0.52
Previous  infections,  n  (%)  14(21%)  511(50%)  2.54  1.5—4.32  0.0004
Cardiac  failure,  n  (%)  15(22%)  449(45%)  2.03  1.21—3.4  0.006
Endocrine  diseases,  n  (%) 9(13%)  238(24)  1.8  0.93—3.51  0.08
Renal  impairment,  n  (%) 4(6%)  31(3%)  0.53  0.2—1.51  0.23
Hepatic  failure,  n  (%) 2(3%)  32(3%)  1.1  0.26—4.61  0.9
Thoracic  surgery,  n  (%) 2(3%)  27(3%)  0.93  0.22—3.92  0.924
Stroke,  n  (%) 14(21%)  287(29%)  1.4  0.82—2.4  0.215
VAP,  n 6 36 — — —
VAP  rate  per  1000  MV  days 52.63  15.32  0.3  0.12—0.7  0.003
VAP, ventilator-associated pneumonia; MV, mechanical ventilator; RR, relative risk; CI, conﬁdence interval; SD, standard deviation;
ASIS, average severity of illness score.
a Bed-days are the total number of days that patients were in the ICU during the selected time period.
b MV-days: the total number of days of exposure to mechanical ventilation by all of the patients in the selected population
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c MV use ratios were calculated by dividing the total numbe
t-test  for  continuous  variables.  We  calculated  95%
conﬁdence  intervals  (CI)  using  VCStat  (Castiglia).
Relative risk  (RR)  ratios  with  95%  conﬁdence  inter-
vals (CI)  were  calculated  for  the  comparison  of
rates of  VAP  using  EPI  Info  V6.  P-values  <  0.05  by
two-sided  tests  were  considered  signiﬁcant.  Fur-
thermore,  we  explored  the  change  in  VAP  rates
following  an  ICU  joining  the  INICC  by  stratifying
the follow-up  period  into  three-month  periods  over
the ﬁrst  year  and  six-month  periods  over  the  sec-
ond and  third  years,  which  then  transitioned  to
yearly review.  We  also  performed  an  additional
regression considering  ‘‘time  since  the  ICU  started
the intervention  period’’  as  a  continuous  variable
(excluding  the  baseline  period)  and  calculated  the
RR for  reduction  in  DAI  for  each  three-month  period
of follow  up.
ResultsDuring  the  study  period,  there  were  1075  patients
hospitalized  for  6011  days  in  the  participating  AICU.
We recorded  2464  mechanical  ventilator  (MV)-days
(Table 1).
1
1
0
rV-days by the total number of Bed-days.
Regarding  patient  characteristics,  we  found  that
atient age,  gender,  pulmonary  disease,  abdominal
urgery,  trauma,  endocrine  disease,  renal  impair-
ent, hepatic  failure,  thoracic  surgery  and  stroke
ere similar  during  both  periods.  However,  previous
nfection  and  cardiac  failure  were  more  prevalent
uring the  intervention  period.  (Table  1)
MV duration  mean  was  similar  during  both
hases, whereas  MV  use  mean  was  higher  during
he intervention  period  (Table  1).
Process  surveillance  for  HH  compliance  was  mea-
ured during  Phase  2,  from  September  2008  to
ovember  2010.  We  recorded  434  opportunities  for
H and  244  compliance  opportunities,  showing  a
ompliance  rate  of  56%  (95%  CI:  51—61)  by the  end
f the  study  period.  HH  compliance  was  not  mea-
ured during  the  baseline  period.
Due to  budgetary  limitations,  we  did  not  collect
ata regarding  the  other  individual  interventions
ncluded in  our  bundle  for  VAP  prevention.
During  baseline,  the  VAP  rate  was  52.63  VAPs  per
000 MV-days,  whereas  the  VAP  rate  was  15.32  per
000 MV  days  during  intervention  (RR  0.3;  95%  CI
.12—0.7; P  0.003).  These  results  showed  a  70%  VAP
ate reduction  (Table  1).
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Table  2  ventilator-associated  pneumonia  rates  stratiﬁed  by  ICU  length  of  participation  in  INICC  and  obtained  by
poisson  regression  analysis.
Months  since  joining  INICC  MV-days  VAP  Crude  VAP
rate/1000  MV
days
RR  (95%  CI)  P-Value
1—3  months  (baseline)  114 6 52.63  —  1
4—12  months  557 8 14.36  0.27  (0.09—0.79)  0.0099
Second  year 686 15 22 0.42  (0.16—1.07) 0.0604
Third  year 545 10 18.35  0.35  (0.13—0.96) 0.0326
Fourth  year  562  3  5.34  0.10  (0.03—0.41)  0.0001
INICC, International Nosocomial Infection Control Consortium, VAP, ventilator-associated pneumonia; MV, mechanical ventilator;
RR, relative risk; ICU, intensive care unit.
In  comparison  to  the  baseline  VAP  rates  for  the
3 months  before  the  intervention,  VAP  rates  were
reduced  by  73%  after  9  months  of  participation
(from 52.63  to  14.36  VAPs  per  1000  MV-days.)  This
rate was  further  reduced  by  58%  during  the  second
year  (from  52.63  to  22  VAPs  per  1000  MV-days),  75%
during the  third  year  (from  52.63  to  18.35  VAPs  per
1000 MV-days)  and  90%  during  the  fourth  year  (from
52.63 to  5.34  VAPs  per  1000  MV-days)  (Table  2).
Regarding the  microorganism  proﬁle,  we  found
that during  phase  1,  the  predominant  agent
detected was  Acinetobacter,  whereas  Pseu-
domonas spp.  and  Klebsiella  were  the  predominant
agents identiﬁed  during  Phase  2 (Table  3).
Discussion
According  to  the  scientiﬁc  literature  from  devel-
oped [2]  and  developing  countries  [1,4],  the  most
serious adverse  effects  of  VAP  include  increased
mortality rates  [1],  signiﬁcant  morbidity  [29],  and
increased LOS  [1].  Additionally,  VAP  is  responsible
for higher  hospital  costs,  as  stated  in  studies  from
both developed  [2]  and  developing  countries  [1].
In developing  countries,  many  health  care  facili-
ties do  not  apply  infection  control  programs,  and
Table  3  Microorganism  proﬁles  of  ventilator-
associated  pneumonia  in  the  participating  adult
intensive  care  unit  for  Phase  1  and  Phase  2.
Isolated  microorganisms  Baseline  Intervention
Acinetobacter  spp.  %  (n)  100%  (1)  7%  (1)
Pseudomonas  spp.  %  (n)  0%  (0)  36%  (5)
Klebsiella  %  (n)  0%  (0)  29%  (4)
Escherichia  coli  %  (n)  0%  (0)  14%  (2)
Pneumococcus  %  (n)  0%  (0)  7%  (1)
Staphylococcus  spp.  %  (n)  0%  (0)  7%  (1)
Total  %  (n)  100%  (1)  100%  (14)
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ihe  incidence  of  VAP  in  the  ICU  setting  remains
bscure [4].  Other  studies  from  limited-resource
ountries  have  reported  that  the  rates  of  VAP  were
ore than  three-fold  higher  than  those  in  devel-
ped  countries  [9—11,30].  In  the  current  study,  the
aseline rate  of  VAP  (52.63  per  1000  MV-days)  was
ore than  twenty-ﬁve  times  higher  than  that  in
he US  (1.8  VAP  rate  per  1000  MV-days  determined
y the  CDC/NSHN)  [31]  and  more  than  eight-fold
igher than  the  rate  of  6.8  reported  by  KISS  [32].
As compared  to  the  VAP  rates  from  other  devel-
ping countries,  the  VAP  baseline  rate  obtained
n the  current  study  was  much  higher  than  those
ublished  by  international  INICC  reports  in  2006
24.1 VAPs  per  1000  MV-days)  [9],  in  2008  (19.5
APs per  1000  MV-days)  [10],  in  2010  (13.16  VAPs
er 1000  MV-days)  [30]  and  in  2012  (15.8  VAPs  per
000 MV-days)  [11].  To  our  knowledge,  the  only  pub-
ished reference  indexed  in  Pubmed/Medline  that
ddressed  the  burden  of  VAP  in  AICUs  in  Cuba  was
 study  on  DAI  rates  conducted  in  two  Cuban  INICC
ember  hospitals,  in  which  the  VAP  rate  was  52.5
APs per  1000  MV-days  [33].
The considerable  inﬂuence  that  socioeconomic
tatus and  hospital  type  have  on  DAIs  in  develop-
ng countries  has  been  assessed  in  very  few  studies
34]. Regarding  the  hospital  type,  VAP  rates  in  pedi-
tric ICUs  from  academic  hospitals  were  higher
han those  in  private  or  public  hospitals  at  8.3  vs.
.5 VAPs  per  1000  MV-days,  respectively  [34].  With
egard to  the  socioeconomic  level,  it  was  shown
hat lower-middle-income  countries  had  higher  VAP
ates than  upper-middle-income  countries  (9.0  vs.
.5 per  1000  MV-days)  [34].
These  VAP  reduction  strategies  have  been  effec-
ive for  a long  time.  In  developed  countries,  it
as been  demonstrated  that  the  incidence  of  VAP
an be  substantially  reduced  by  more  than  30%
hrough  basic  but  effective  measures,  such  as  hand
ygiene compliance  [20],  semi-recumbent  position-
ng [12],  early  removal  of  endotracheal  tubes  [35]
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and  maintenance  of  endotracheal  cuff  pressure  and
continuous  subglottic  suctioning  [12].  Similarly,  it
was shown  in  studies  conducted  by  the  INICC  that
implementation  of  a  multi-dimensional  approach
for VAP,  including  a  bundle  of  interventions,  educa-
tion, outcome  and  process  surveillance,  feedback
of VAP  rates  and  performance  feedback,  resulted
in signiﬁcant  reductions  in  VAP  rates  in  Argentina
(51.28 vs.  35.50  VAPs  per  1000  MV-days)  [14]  and
China, amounting  to  a  79%  cumulative  VAP  rate
reduction  during  the  3-year  study  period  [36]  and  a
reduction in  the  pooled  VAP  rates  of  pediatric  ICUs
(31% VAP  rate  reduction)  [37],  neonatal  ICUs  (33%
VAP rate  reduction)  [38]  and  adult  ICUs  (55.83%  VAP
rate reduction)  of  limited-resource  countries  [39].
The  INICC  multidimensional  approach  for  VAP
includes six  elements.  The  ﬁrst  element  consists
of the  implementation  of  an  infection  prevention
bundle that  can  be  feasibly  adapted  to  the  ICU  set-
ting in  developing  countries  and  that  is  based  on
the guidelines  published  by  the  SHEA  and  the  IDSA
[12], which  provide  evidence-based  recommenda-
tions and  cost-effective  infection  control  measures.
The second  element  consists  of  the  education  of
HCWs about  infection  prevention  measures.  Third,
VAP outcome  surveillance  should  apply  the  deﬁ-
nitions  for  DAI  developed  by  the  U.S.  CDC/NHSN
[16,17]. Fourth,  VAP  process  surveillance  should
monitor  compliance  HH  performance.  Fifth,  feed-
back should  be  provided  on  VAP  rates  and  sixth,
performance feedback,  particularly  by  reviewing
and discussing  chart  results  at  monthly  infection
control meetings,  should  occur.
In this  study,  patient  characteristics,  such
as age,  gender,  pulmonary  disease,  abdominal
surgery, trauma,  endocrine  disease,  renal  impair-
ment,  hepatic  failure,  thoracic  surgery  and  stroke,
were similar  during  both  periods  and  therefore
demonstrated similar  levels  of  patient  intrinsic
risk. However,  previous  infection  and  cardiac  fail-
ure were  more  prevalent  during  the  intervention
period, as  well  as  the  MV  mean,  suggesting  that
patient  intrinsic  risk  was  higher  during  the  inter-
vention  period.  In  the  implementation  of  the  INICC
multidimensional  approach,  we  found  that  HH  com-
pliance rate  was  56%  in  Phase  2.
During the  study  period,  the  high  VAP  rate  at
baseline  was  reduced  from  52.63  to  15.32  per
1000 MV  days  (RR  0.3;  95%  CI  0.12—0.7;  P  0.003),
showing a  70%  VAP  rate  reduction.  As  compared  to
the baseline  VAP  rates  for  the  3 months  before  the
intervention,  the  VAP  rates  were  reduced  by  73%
after 9  months  of  participation.  Moreover,  this  rate
was further  reduced  by  58%  during  the  second  year,
75% during  the  third  year  and  90%  during  the  fourth
year.
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Regarding  the  microorganism  proﬁle,  we  iden-
iﬁed a  predominance  of  Pseudomonas  and  Acine-
obacter  spp.  in  Phase  1  and  a  predominance  of
seudomonas  spp  and  Klebsiella  in  Phase  2.  Accord-
ng to  the  scientiﬁc  literature  from  Cuba,  the
redominant agents  reported  for  VAPs  are  Kleb-
iella  pneumoniae,  Pseudomona  Aeruginosa  and
nterobacter  [40].
tudy limitations
here  were  several  limitations  of  this  study.
First, the  study  ﬁndings  cannot  be  generalized
o all  AICU  patients  from  Cuba;  however,  this  study
emonstrated  that  a  multidimensional  approach  is
undamental for  understanding  and  combating  the
dverse effects  of  VAP  in  the  AICU  setting  in  Cuba.
Second, the  three-month  baseline  period  may
ave been  too  short  and  may  have  overestimated
he effect  of  the  intervention.  Nevertheless,  dur-
ng the  baseline  period,  the  sample  size  was  large
nough,  and  the  CIs  for  the  baseline  rate  were  nar-
ow. In  addition,  this  length  for  a baseline  period  is
ommonly reported  in  the  scientiﬁc  literature.
Third, we  were  unable  to  perform  process
urveillance for  HH  compliance  during  baseline
s well  as  for  the  following  bundle  components:
aintenance  of  patients  in  a semi-recumbent  posi-
ion (30—45◦ elevation  of  the  head  of  the  bed);
erformance of  daily  assessments  of  readiness  to
ean and  use  of  weaning  protocols;  performance
f regular  oral  care  with  an  antiseptic  solution;
se of  noninvasive  ventilation  whenever  possible
nd minimization  of  the  duration  of  ventilation;
referable use  of  orotracheal  instead  to  nasotra-
heal intubation;  maintenance  of  an  endotracheal
uff pressure  of  at  least  20  cm  H2O;  removal  of
he condensate  from  ventilator  circuits  and  keep-
ng the  ventilator  circuit  closed  during  condensate
emoval; change  of  the  ventilator  circuit  only
hen visibly  soiled  or  malfunctioning;  avoidance
f gastric  overdistention;  avoidance  of  histamine
eceptor  2 (H2)-blocking  agents  and  proton  pump
nhibitors;  and  the  use  of  sterile  water  to  rinse
eusable  respiratory  equipment.  We  were  also
nable  to  collect  sufﬁcient  information  on  other
on-quantiﬁable  interventions  included  in  our  mul-
idimensional  approach,  such  as  education  and
raining.  During  the  study  period,  we  did  not  possess
he necessary  resources  to  collect  more  data  on
rocess  surveillance  and  measure  compliance  with
hese interventions.  Therefore,  we  could  not  evalu-
te their  individual  implications  or  other  contextual
actors  related  to  the  ICU  or  hospital.  These  data
ould greatly  advance  the  knowledge  on  quality
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Sffectiveness  of  a  multidimensional  approach  for  th
mprovement  in  Cuban  hospitals.  Nevertheless,  our
ain goal  was  to  reduce  the  high  baseline  VAP  rates
ound in  our  ICU,  and  although  our  interventions
ere inexpensive,  the  individual  evaluation  would
ave required  greater  allocation  of  time,  thereby
ontributing  to  unnecessary  harm  for  ICU  patients.
ortunately, as  of  January  2012,  we  have  been  able
o collect  all  of  these  process  surveillance  data.
onclusions
his  study  is  among  the  ﬁrst  to  report  a  substantial
eduction in  VAP  rates  in  the  AICU  setting,  thereby
emonstrating  that  this  type  of  infection  control
pproach is  successful  [4].  Despite  higher  patient
ntrinsic  risk  characteristics  during  Phase  2,  infec-
ion control  professionals  at  the  AICU  setting  of
his INICC  member  Cuban  hospital  were  able  to
chieve  successful  control  of  VAP.  It  is  worth  high-
ighting  that  the  reduction  in  VAP  rates  did  not
ccur  due  to  surveillance  alone.  These  data  should
erve as  a  guide  for  infection  control  profession-
ls as  to  what  strategies  should  be  attempted  for
mprovement  of  patient  care  practices,  such  as  per-
ormance feedback  [14,41].  Therefore,  to  obtain
he greatest  beneﬁt  from  preventive  strategies,  it  is
ssential to  support  educational  efforts  with  regu-
ar feedback  of  monthly  incidence  rates  of  VAPs  and
erformance  feedback  of  all  bundle  components  in
ddition to  HH  compliance  rates,  as  shown  in  differ-
nt studies  carried  out  in  INICC  member  hospitals
14,41—43,15].
The successful  preventive  strategies  shown  in
his study  were  adopted  as  part  of  the  multidi-
ensional approach  for  VAP  prevention  in  hospital
nfection  control  programs  worldwide  and  have  led
o signiﬁcant  VAP  reductions.  As  part  of  the  INICC
etwork,  investigators  are  freely  provided  with
raining  and  methodological  tools  to  perform  out-
ome and  process  surveillance  and  to  implement
n effective  infection  prevention  model  for  VAPs.
t the  same  time,  the  publication  of  these  ﬁndings
erves  to  foster  relevant  scientiﬁc  evidence-based
iterature. For  this  reason,  we  invite  hospitals
orldwide to  participate  in  the  INICC  project,
hich was  set  up  to  respond  to  the  compelling
eed in  limited-resource  settings  to  signiﬁcantly
revent, control  and  reduce  VAPs  and  their  adverse
ffects.unding
he  funding  for  the  activities  carried  out  at
he INICC  headquarters  was  provided  by  the
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